Does Antibiotic Resistance Evolve in Hospitals?
Authors:
Anna Seigal,
Portia Mira,
Bernd Sturmfels,
Miriam Barlow
Abstract:
Nosocomial outbreaks of bacteria are well-documented. Based on these incidents, and the heavy usage of antibiotics in hospitals, it has been assumed that antibiotic resistance evolves in hospital environments. To test this assumption, we studied resistance phenotypes of bacteria collected from patient isolates at a community hospital over a 2.5-year period. A graphical model analysis shows no asso…
▽ More
Nosocomial outbreaks of bacteria are well-documented. Based on these incidents, and the heavy usage of antibiotics in hospitals, it has been assumed that antibiotic resistance evolves in hospital environments. To test this assumption, we studied resistance phenotypes of bacteria collected from patient isolates at a community hospital over a 2.5-year period. A graphical model analysis shows no association between resistance and patient information other than time of arrival. This allows us to focus on time course data.
We introduce a Hospital Transmission Model, based on negative binomial delay. Our main contribution is a statistical hypothesis test called the Nosocomial Evolution of Resistance Detector (NERD). It calculates the significance of resistance trends occurring in a hospital. It can inform hospital staff about the effects of various practices and interventions, can help detect clonal outbreaks, and is available as an R-package.
We applied the NERD method to each of the 16 antibiotics in the study via 16 hypothesis tests. For 13 of the antibiotics, we found that the hospital environment had no significant effect upon the evolution of resistance; the hospital is merely a piece of the larger picture. The p-values obtained for the other three antibiotics (Cefepime, Ceftazidime and Gentamicin) indicate that particular care should be taken in hospital practices with these antibiotics. One of the three, Ceftazidime, was significant after accounting for multiple hypotheses, indicating a trend of decreased resistance for this drug.
△ Less
Submitted 18 October, 2016; v1 submitted 11 May, 2016;
originally announced May 2016.
Rational Design of Antibiotic Treatment Plans
Authors:
Portia M. Mira,
Kristina Crona,
Devin Greene,
Juan C. Meza,
Bernd Sturmfels,
Miriam Barlow
Abstract:
The development of reliable methods for restoring susceptibility after antibiotic resistance arises has proven elusive. A greater understanding of the relationship between antibiotic administration and the evolution of resistance is key to overcoming this challenge. Here we present a data-driven mathematical approach for developing antibiotic treatment plans that can reverse the evolution of antib…
▽ More
The development of reliable methods for restoring susceptibility after antibiotic resistance arises has proven elusive. A greater understanding of the relationship between antibiotic administration and the evolution of resistance is key to overcoming this challenge. Here we present a data-driven mathematical approach for developing antibiotic treatment plans that can reverse the evolution of antibiotic resistance determinants. We have generated adaptive landscapes for 16 genotypes of the TEM beta-lactamase that vary from the wild type genotype TEM-1 through all combinations of four amino acid substitutions. We determined the growth rate of each genotype when treated with each of 15 beta-lactam antibiotics. By using growth rates as a measure of fitness, we computed the probability of each amino acid substitution in each beta-lactam treatment using two different models named the Correlated Probability Model (CPM) and the Equal Probability Model (EPM). We then performed an exhaustive search through the 15 treatments for substitution paths leading from each of the 16 genotypes back to the wild type TEM-1. We identified those treatment paths that returned the highest probabilities of selecting for reversions of amino acid substitutions and returning TEM to the wild type state. For the CPM model, the optimized probabilities ranged between 0.6 and 1.0. For the EPM model, the optimized probabilities ranged between 0.38 and 1.0. For cyclical CPM treatment plans in which the starting and ending genotype was the wild type, the probabilities were between 0.62 and 0.7. Overall this study shows that there is promise for reversing the evolution of resistance through antibiotic treatment plans.
△ Less
Submitted 5 June, 2014;
originally announced June 2014.
